Prevention of Contrast Induced Nephropathy With Sodium Bicarbonate (PROMEC)
Primary Purpose
Acute Kidney Failure
Status
Completed
Phase
Phase 2
Locations
Colombia
Study Type
Interventional
Intervention
Bicarbinate 150 mEq/L
Sponsored by
About this trial
This is an interventional prevention trial for Acute Kidney Failure focused on measuring bicarbonate, nephropathy, contrast
Eligibility Criteria
Inclusion Criteria:
- 18+ years of age
Inpatient at Hospital Universitario San Vicente de Paúl scheduled to undergo diagnostic CT scan using contrast or angiography and either
- Serum creatinine 1.2 mg/dl or more, or
- Type 2 Diabetes Mellitus
Exclusion Criteria:
- Current clinical diagnosis of exacerbated congestive heart failure
- Exposure to contrast 30 days prior to study
- Allergy to contrast dye
- Chronic renal disease with dialysis therapy
- Acute renal failure with dialytic urgency
- Urgency procedure needed
- Systolic blood pressure < 90 or vasopressor support
- No authorization by patient or physician in charge
- Serum potassium < 3 mEq/L
- Ejection fraction < 35% by previous echocardiography
- Acute pulmonary edema in previous 48 hours
Sites / Locations
- Hospital Universitario San Vicente Paúl
Outcomes
Primary Outcome Measures
development of contrast induced nephropathy, defined as an increase in serum creatinine of 25% or more within 48 h after administration of contrast
Secondary Outcome Measures
change in serum bicarbonate; change in serum potassium; change in serum creatinine
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00472563
Brief Title
Prevention of Contrast Induced Nephropathy With Sodium Bicarbonate
Acronym
PROMEC
Official Title
Prevention of Contrast Induced Nephropathy With Sodium Bicarbonate
Study Type
Interventional
2. Study Status
Record Verification Date
April 2008
Overall Recruitment Status
Completed
Study Start Date
May 2007 (undefined)
Primary Completion Date
February 2008 (Actual)
Study Completion Date
February 2008 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Universidad de Antioquia
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Deterioration of kidney renal function occurs in a minority of people due to contrast-required procedures. The purpose of this study is to compare two different interventions to reduce the risk of kidney injury after contrast medium exposition.
We will perform a randomized clinical trial following a modification of a previously published protocol (Merten et al.JAMA 2004;291(19):2328-34). Patients will be randomly assigned to one of two groups of treatment. Group A will receive 1 cc/kg/hour of 0.9% saline infusion starting 12 hours before and continuing 12 hours after the procedure. Group B will receive 3 cc/kg of sodium bicarbonate solution for one hour prior to procedure, then drip rate will be decreased to 1 cc/kg/hour until 6 hours post procedure.
Detailed Description
We will perform a randomized clinical trial following a modification of a previously published protocol (Merten et al.JAMA 2004;291(19):2328-34). Patients will be randomly assigned to one of two groups of treatment. Group A will receive 1 cc/kg/hour of 0.9% saline infusion starting 12 hours before and continuing 12 hours after the procedure. Group B will receive 3 cc/kg of sodium bicarbonate solution for one hour prior to procedure, then drip rate will be decreased to 1 cc/kg/hour until 6 hours post procedure.
Phase 2/3 study Study Type: Interventional Study Design: Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study.
Subjects: Consecutive samples of all inpatients who meet the inclusion criteria
Primary outcomes: Development of contrast induced nephropathy, defined as an increase in serum creatinine of 25% or more within 48 h after administration of contrast.
Secondary outcomes: change in serum bicarbonate; change in serum potassium; change in serum creatinine.
Expected total enrollment: 212
Allocation Assignment: Patients who meet inclusion criteria and agree to participate in the study will be assigned by a random number table to saline or bicarbonate, using closed envelopes and stratifying according to history of diabetes and type of procedure (cardiac catheterism or others).
Condition: Contrast Induced Nephropathy
Intervention: 75 cc of sodium bicarbonate (8.4%) mixed in 425 cc of D5W
Gender: both Age: 18+ years of age Recruitment Status: participants are currently being recruited
Facility location:
Universidad de Antioquia, Internal Medicine Department; Hospital Universitario San Vicente de Paul. Medellin, Colombia.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Kidney Failure
Keywords
bicarbonate, nephropathy, contrast
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
Single
Allocation
Randomized
Enrollment
212 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Bicarbinate 150 mEq/L
Intervention Description
75 cc of sodium bicarbonate (8.4%) mixed in 425 cc of D5W
Primary Outcome Measure Information:
Title
development of contrast induced nephropathy, defined as an increase in serum creatinine of 25% or more within 48 h after administration of contrast
Time Frame
48 h
Secondary Outcome Measure Information:
Title
change in serum bicarbonate; change in serum potassium; change in serum creatinine
Time Frame
48 h
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Eligibility Criteria
Inclusion Criteria:
18+ years of age
Inpatient at Hospital Universitario San Vicente de Paúl scheduled to undergo diagnostic CT scan using contrast or angiography and either
Serum creatinine 1.2 mg/dl or more, or
Type 2 Diabetes Mellitus
Exclusion Criteria:
Current clinical diagnosis of exacerbated congestive heart failure
Exposure to contrast 30 days prior to study
Allergy to contrast dye
Chronic renal disease with dialysis therapy
Acute renal failure with dialytic urgency
Urgency procedure needed
Systolic blood pressure < 90 or vasopressor support
No authorization by patient or physician in charge
Serum potassium < 3 mEq/L
Ejection fraction < 35% by previous echocardiography
Acute pulmonary edema in previous 48 hours
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Wilmar A Maya Salazar, MD
Organizational Affiliation
Universidad de Antioquia
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Julián M Aristizábal, MD
Organizational Affiliation
Universidad de Antioquia
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Oscar M Santos, MD
Organizational Affiliation
Universidad de Antioquia
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
John F Nieto, MD
Organizational Affiliation
Universidad de Antioquia
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Liliana Jaramillo, MD
Organizational Affiliation
Universidad de Antioquia
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Jorge I García, MD
Organizational Affiliation
Universidad de Antioquia
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Fabian A Jaimes, MD
Organizational Affiliation
Universidad de Antioquia
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Alvaro García, MD
Organizational Affiliation
Universidad de Antioquia
Official's Role
Study Chair
Facility Information:
Facility Name
Hospital Universitario San Vicente Paúl
City
Medellín
State/Province
Antioquia
ZIP/Postal Code
57
Country
Colombia
12. IPD Sharing Statement
Learn more about this trial
Prevention of Contrast Induced Nephropathy With Sodium Bicarbonate
We'll reach out to this number within 24 hrs